Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al

Affiliations

• ¹ Sanofi Genzyme, Cambridge, Massachusetts, USA.
• ² Department of Neurology, UCSF, San Francisco, California, USA.
• ³ Department of Neurosurgery, UCSF, San Francisco, California, USA.
• ⁴ Department of Pediatrics, UCSF, San Francisco, California, USA.
• ⁵ Children's University Hospital, Zurich, Switzerland.
• ⁶ 3T Biosciences Inc, Palo Alto, California, USA.
• ⁷ Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
• ⁸ Department of Microbiology and Immunology, UCSF, San Francisco, California, USA.
• ⁹ Department of Neurosurgery, UCSF, San Francisco, California, USA hideho.okada@ucsf.edu.
• ¹⁰ Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.